Profile
Sector:
HealthcareCountry:
United StatesIPO:
25 June 2014Website:
http://www.amphastar.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 71 min agoDividend
Analysts recommendations
Institutional Ownership
AMPH Latest News
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that on June 3, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.
Seeking Alpha's screener identified Amphastar Pharmaceuticals as a potential investment candidate based on its solid financials, positive growth in revenue and earnings. Despite its strong financials and potential for earnings growth, the company's stock fell 31% in 5 months. The article aims to uncover the reasons behind the price decline to determine if the price decline is a temporary setback that offers an opportunity for value investors.
Amphastar (AMPH) has the ideal mix of factors to potentially exceed earnings expectations in its upcoming report. Be ready with the important predictions.
Amphastar (AMPH) has a strong track record of exceeding earnings expectations and is well positioned to potentially beat estimates in its upcoming quarterly report.
AMPH, BCML, and DHC were placed on the Zacks Rank #5 (Strong Sell) List on April 26, 2024.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $43.21, representing a -0.96% change from its previous close.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript
What type of business is Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
What sector is Amphastar Pharmaceuticals in?
Amphastar Pharmaceuticals is in the Healthcare sector
What industry is Amphastar Pharmaceuticals in?
Amphastar Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is Amphastar Pharmaceuticals from?
Amphastar Pharmaceuticals is headquartered in United States
When did Amphastar Pharmaceuticals go public?
Amphastar Pharmaceuticals initial public offering (IPO) was on 25 June 2014
What is Amphastar Pharmaceuticals website?
https://www.amphastar.com
Is Amphastar Pharmaceuticals in the S&P 500?
No, Amphastar Pharmaceuticals is not included in the S&P 500 index
Is Amphastar Pharmaceuticals in the NASDAQ 100?
No, Amphastar Pharmaceuticals is not included in the NASDAQ 100 index
Is Amphastar Pharmaceuticals in the Dow Jones?
No, Amphastar Pharmaceuticals is not included in the Dow Jones index
When does Amphastar Pharmaceuticals report earnings?
The next expected earnings date for Amphastar Pharmaceuticals is 08 August 2024